The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia

ConclusionBoth doses of once-weekly semaglutide represent cost-saving treatment options versus dulaglutide 1.5  mg for obese patients with type 2 diabetes in Slovakia.FundingNovo Nordisk A/S.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research